Analyst consensus rating
Rhythm Pharmaceuticals Analyst Rating: Strong Buy
RYTM is rated Strong Buy by 15 analysts with a $141.53 target. As of 2026-08-25.
Direct answer
Rhythm Pharmaceuticals's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $141.53.
Forecast evidence checked August 25, 2026.
Get free Rhythm Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $112.17
- Average price target
- $141.53
- High price target
- $160.00
- Low price target
- $105.00
- Low target gap
- -6.4%
- Target upside
- +26.2%
- High target gap
- +42.6%
- Target range width
- 49%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $141.53.
How far are Rhythm Pharmaceuticals's low and high targets from the recorded price?
The low target implies -6.4%, while the high target implies +42.6%.
How many analysts are included in Rhythm Pharmaceuticals's consensus?
The verified consensus includes 15 analysts.
How is Rhythm Pharmaceuticals's target upside or downside calculated?
The average target of $141.53 is divided by the recorded price of $112.17, then one is subtracted to produce +26.2%. This does not guarantee a future return.
When was Rhythm Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.